Therapy of low-grade non-Hodgkin's lymphoma (NHL) with anti-CD20 specific antibodies (Rituximab) has recently been approved for the treatment of follicular and relapsed or refractory NHL in various countries. Rituximab has shown efficacy without concomitant chemotherapy [1] [2] [3] [4] , suggesting a new therapeutic principle that probably includes apoptosis induction [5, 6] . To our knowledge, little experience and no published information exists on the use of Rituximab in multiple myeloma. We report the case of a patient in whom Rituximab was used as fourth line therapy of multiple myeloma. Rapid acceleration of tumor progression during anti-CD20 therapy was seen, suggesting that Rituximab promoted tumor growth.
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In April 1997, a 54-year-old white male with sequelae of a poliomyelitic infection in childhood presented with progressive back pain on thoracic level 8/9. Complete work-up revealed an osteolytic fracture of the eighth thoracic vertebrae, osteolytic lesions of ribs, the left humerus and skull. Vertebral biopsy showed infiltration by malignant plasma cells that were mostly CD20-positive (see Figure 1 ), bone marrow infiltration was < 5%. Immunofixation revealed a monoclonal IgG lambda gammopathy. The vertebral fracture was stabilized by dorsal spondylodesis and the patient was enrolled in a clinical trial using VMCP (vincristine, alkeran, cyclophosphamide and prednisone) polychemotherapy and interferon-oc. After three cycles, progressive osteolytic rib lesions were noted and an anthracycline based polychemotherapy with epirubicin, vincristine and prednisone (VAP) as well as biphosphonate therapy (pamidronate) were started. With a good partial response achieved after six cycles (the paraprotein dropped from 9.64 g/1 to 5.98 g/1), VAP was halted but pamidronate was continued. Follow-up showed a slow but steady increase in paraprotein concentration, reaching 10.8 g/1 at three months after VAP chemotherapy. At that time, the patient refused any new cytotoxic chemotherapy but did agree to treatment with prednisone only (25 mg/m 2 p.o.) in addition to pamidronate. But continued tumour progression with an osteolytic right collar-bone fracture was documented, necessitating local radiotherapy. The patient again refused cytotoxic therapy including high-dose chemotherapy. Given the CD20-positivity of the tumor (Figure 1 ), a compassionate use therapy with Rituximab (anti-CD20 antibody) was offered. Therapy was initiated at 375 mg/m 2 i.v. weekly for a total of four doses; therapy with pamidronate was still continued. During the four weeks of Rituximab therapy, a steep rise in the paraprotein concentration was seen (see Figure 2) . Within 14 days, the paraprotein concentration rose from 13.3 to 17.2 g/1, which is a 30% increase. Also, a new osteolytic left collar-bone fracture and progression of the lesion in the left humerus occurred. Given these evidences of rapid tumor progression, Rituximab therapy was stopped; the patient now agreed to reinitiate VAP polychemotherapy. Although the paraprotein concentration leveled-off at this point (see Figure 2) , an osteolytic left femoral fracture occurred that required prosthetic hip replacement. Interestingly, IL-6 was increased early during the reinitiated chemotherapy (36.5 pg/ml; reference range <3.1 pg/ml) [7] but decreased (to 5.2 pg/ml) within three days. In this context, the continued increase of the Figure 2 . The course of the paraprotein concentration before (rhomboids), during (squares) and after (open circles) anti-CD20 therapy is displayed; the dotted line represents a trend based on a linear regression analysis of the paraprotein concentrations measured before Rituximab therapy. A steep increase in the paraprotein concentration can be seen after initiation of anti-CD20 therapy (a 30% increase occuring within 14 days); later on, the paraprotein finally decreases with reinstitution of the VAP regimen. Immediately after cessation of the Rituximab therapy and at the beginning of the VAP regimen, a dramatic decrease in IL-6 concentration was observed (36.5 to 5.2 pg/ml within three days, open triangles). With later tumor progression, IL-6 concentrations increased again to 73.1 pg/ml. paraprotein for another eight weeks (see Figure 2) argues against an early response to the reinitiated chemotherapy (although this possibility can not be completely ruled out). Thus, the question whether the abrupt decrease in IL-6 could be attributed to a 'Rituximab withdrawal' remains open. However, IL-6 went in parallel with tumor progression five months after Rituximab therapy, when concentrations increased again to 57.9 pg/ml and later 73.1 pg/ml.
Despite the possibility that tumor progression during Rituximab therapy occurred by coincidence, a causal relationship is more likely. The steep rise in the paraprotein concentration occurred exactly with the beginning of Rituximab therapy and was leveling off thereafter. Direct stimulation through the antibody seems unlikely since anti-CD20 antibodies have been shown to induce or enhance apoptosis [5, 6, 8] although an anti-CD20 antibody (1F5) that promotes cell cycle progression in non-germinal center B cells and protection from apoptosis in germinal center B cells has been described [9] . On the other hand, the fast decrease in IL-6 concentration after stopping Rituximab therapy was stunning, but overlap with the reinitiated chemotherapy prevents any firm conclusions on a possible decrease in autocrine IL-6 production [10] as the underlying mechanism. The anti-CD20 antibody itself as an explanation for the increase in the paraprotein can be excluded: the increase in paraprotein was 3.9 g/1 during Rituximab therapy but the total amount of anti-CD20 antibody given was only 0.47 g/1 assuming a whole blood volume of six liters.
Recent data suggest that not only tumors in single patients but up to 20% of all multiple myeloma might be CD20-positive [11, 12] , Therefore, more information based on clinical trials data on the use of Rituximab in multiple myeloma is needed in order to explore it as an additional treatment strategy in this specific subset of patients.
For now, given our experience in the patient we describe, we would suggest close observation of biochemical (paraprotein quantification) and clinical parameters in myeloma patients undergoing Rituximab therapy. Newer ways of monitoring disease activity might also be helpful (e.g., IL-6 measurements). Immediate cessation of Rituximab therapy should be considered if any clinical signs of tumor progression, sudden increase in the paraprotein concentration and/or IL-6 level occurs.
